Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0545120000100030399
Journal of Microbiology and Biotechnology
2000 Volume.10 No. 3 p.399 ~ p.404
MDP-Lys (L18),a Synthetic Muramyl Dipeptide Derivative,Enhances Antitumor Activity of an Inactivated Tumor Vaccine
Yoo, Young Choon
Park, Seung Yong/Lee, Kyung Bok/Ichiro Azuma
Abstract
The adjuvant effect of a muramyl dipeptide (MDP) derivative, MDP-Lys (L18), on enhancing of antitumor immunity induced by X-irradiated tumor cells against highly metastatic B16-BL6 melanoma cells was examined in mice. Mice immunized intradermally (i.d.) with a mixture of Xirradiated B 16-BL6 cells and MDP-Lys (L18) [Vac+MDP-Lys (L18)] followed by an intravenous (i.v.) inoculation of 10^4 viable tumor cells 7 days after immunization, showed a significant inhibition of experimental lung metastasis of B16-BL6 melanoma cells. The most effective immunization for the prophylactic inhibition of tumor metastasis was obtained from the mixture of 100§¶ of MDP-Lys (L18) and 10^4 X-irradiatied tumor vaccine. Furthermore, immunization of mice with Vac+MDP-Lys (L 18), 3 days after tumor challenge, resulted in a significant inhibition of lung metastasis of B16-BL6 melanoma cells in an experimental lung metastasis model. Similarly, the administration of Vac+MDP-Lys (L18), 1 or 7 days after tumor removal, markedly inhibited tumor metastasis of B 16-BL6 in a spontaneous lung metastasis model. When Vac+MDP-Lys (L18) was i.d. administered 3 days after subcutaneous (s.c.) inoculation of tumor cells (5¡¿10 exp(5)/site) on the back, mice treated with Vac+MDP-Lys (L18) showed inhibition of significantly tumor growth,on day 20. These results suggest that MDP-Lys (L18) is able to enhance antitumor activity induced by X-irradiated tumor vaccine to reduce lung metastasis of tumor cells, and is a potent immunomodulating agent which may be applied prophylactically as well as therapeutically to treatment of cancer metastasis.
KEYWORD
FullTexts / Linksout information
Listed journal information
SCI(E) MEDLINE ÇмúÁøÈïÀç´Ü(KCI)